Skip to main content
Contact us
General contacts
Inmunization devices key contacts
In Vitro Diagnostics Key Contacts
Vaccines Key Contacts
Medicines Key Contacts
Vector Control Products Key Contacts
Inspection Services Key Contacts
Glossary and Acronyms
FAQ
Complaints
Feedback
Main Menu Level 1
Home
Product Streams
Immunization Devices
In Vitro Diagnostics
Medicines
Vaccines
Vector Control Products
Inspection Services
Events
News
ePQS
About
Search
Search
Documents A to Z
|
1
|
2
|
3
|
4
|
5
|
7
|
8
|
A
|
B
|
C
|
D
|
E
|
F
|
G
|
H
|
I
|
J
|
L
|
M
|
N
|
O
|
P
|
Q
|
R
|
S
|
T
|
U
|
V
|
W
|
Z
|
С
|
ت
M
Notes on the design of bioequivalence study: norethisterone
PDF
M
Notes on the design of bioequivalence study: norethisterone enanthate
PDF
M
Notes on the design of bioequivalence study: norethisterone enanthate/estradiol valerate
PDF
M
Notes on the design of bioequivalence study: norgestrel
PDF
M
Notes on the design of bioequivalence study: norgestrel
PDF
M
Notes on the design of bioequivalence study: oseltamivir
PDF
M
Notes on the design of bioequivalence study: para-aminosalicylic acid
PDF
M
Notes on the design of bioequivalence study: praziquantel
PDF
M
Notes on the design of bioequivalence study: pretomanid
PDF
M
Notes on the design of bioequivalence study: Primaquine
PDF
M
Notes on the design of bioequivalence study: procaine benzylpenicillin
PDF
M
Notes on the design of bioequivalence study: progesterone vaginal ring
PDF
M
Notes on the Design of Bioequivalence Study: Pyrazinamide (6 February 2024)
PDF
M
Notes on the Design of Bioequivalence Study: Pyridoxine (6 February 2024)
PDF
M
Notes on the design of bioequivalence study: pyrimethamine/sulfadoxine
PDF
M
Notes on the design of bioequivalence study: raltegravir
PDF
M
Notes on the design of bioequivalence study: remdesivir
PDF
M
Notes on the design of bioequivalence study: ribavirin
PDF
M
Notes on the design of bioequivalence study: rifabutin
PDF
M
Notes on the design of bioequivalence study: rifampicin
PDF
M
Notes on the design of bioequivalence study: rifampicin/clarithromycin
PDF
M
Notes on the design of bioequivalence study: rifapentine
PDF
M
Notes on the design of bioequivalence study: ritonavir
PDF
M
Notes on the design of bioequivalence study: sofosbuvir
PDF
M
Notes on the design of bioequivalence study: sofosbuvir/daclatasvir
PDF
M
Notes on the design of bioequivalence study: sofosbuvir/ledipasvir
PDF
M
Notes on the design of bioequivalence study: sofosbuvir/velpatasvir
PDF
M
Notes on the design of bioequivalence study: sulfadiazine
PDF
M
Notes on the design of bioequivalence study: Sulfamethoxazole/Trimethoprim
PDF
M
Notes on the design of bioequivalence study: tafenoquine
PDF
M
Notes on the design of bioequivalence study: tenofovir disoproxil fumarate
PDF
M
Notes on the design of bioequivalence study: terizidone
PDF
M
Notes on the design of bioequivalence study: ulipristal acetate
PDF
M
Notes on the design of bioequivalence study: velpatasvir
PDF
M
Notes on the design of bioequivalence study: zanamivir
PDF
M
Notes on the design of bioequivalence study: zidovudine
PDF
M
Notes on the design of bioequivelence study: benzathine benzylpenicillin
PDF
M
Notes on the design of bioequivelence study: emtricitabine/tenofovir/efavirenz
PDF
M
Notes on the design of bioequivelence study: ethambutol/isoniazid (16 January 2018)
PDF
M
Notes on the design of bioequivelence study: ethambutol/isoniazid/pyrazinamide/rifampicin
PDF
M
Notes on the design of bioequivelence study: ethambutol/isoniazid/rifampicin
PDF
M
Notes on the design of bioequivelence study: isoniazid/pyrazinamide/rifampicin
PDF
M
Notes on the design of bioequivelence study: isoniazid/rifampicin
PDF
M
Notes on the design of bioequivelence study: isoniazid/rifapentine
PDF
M
Notes on the design of bioequivelence study: lamivudine/tenofovir/efavirenz
PDF
M
Notes on the design of bioequivelence study: miltefosine
PDF
M
Notes on the design of bioequivelence study: raltegravir
PDF
M
Notes on the design of bioequivelence study: rifapentine
PDF
M
Notes on the design of bioequivelence study: sofosbuvir/velpatasvir
PDF
IVD
Notice of Concern - Access Bio Inc (17 January 2020), Somerset - UNITED STATES
PDF
Pagination
« First
First page
‹‹
Previous page
1
2
3
4
5
››
Next page
Last »
Last page